P F
1 Mar, 2022
Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Effective 1 de maio, 2022, the criteria used for medical necessity review of ExoDx Prostate IntelliScore (EPI) for Medicare Advantage Plans will be updated. Please refer to the draft medical policy for details here.